Comparison of serum biomarkers of myocardial fibrosis with cardiac magnetic resonance in patients operated for tetralogy of Fallot.
Congenital heart disease
Magnetic resonance imaging
Right ventricle
Tetralogy of Fallot
Journal
International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291
Informations de publication
Date de publication:
01 07 2022
01 07 2022
Historique:
received:
21
01
2022
revised:
24
03
2022
accepted:
22
04
2022
pubmed:
30
4
2022
medline:
24
5
2022
entrez:
29
4
2022
Statut:
ppublish
Résumé
Serum biomarkers of myocardial fibrosis are considered markers of adverse outcome in adults with heart disease. Associations between biomarkers and clinical parameters in tetralogy of Fallot (TOF) has been understudied. We compared serum biomarker profiles with clinical and cardiac magnetic resonance (CMR) parameters of ventricular remodeling in patients with repaired TOF. Serum biomarkers [metalloproteinases MMP1 and MMP9, galectin-3, micro-RNA21 (miR21)), ST2, procollagen type I carboxy-terminal propeptide (PICP), and NTproBNP] were measured in TOF patients undergoing CMR. Associations between biomarkers and clinical and CMR variables were assessed using correlation coefficients, and linear and logistic regression. Sixty patients were investigated, of which 47% were male. Age at CMR and TOF repair was 15 years [interquartile range (IQR) 9, 22] and 3.2 months (IQR 0.8, 6.2), respectively. Twelve (20%) had prior pulmonary valve replacement (PVR). MMP1 values were higher among those with prior PVR (16.7 (IQR 7.9, 25.5) vs 14.4 (IQR 9.9, 24.9), p = 0.02). When stratifying MMP1 into low and high groups, higher MMP1 was associated with higher indexed right (RV) and left ventricular (LV) mass and RV mass:volume ratios after adjusting for PVR. No other associations between biomarkers and CMR parameters were identified. Only MMP1 was associated with markers of RV remodeling after TOF repair. As an enzyme involved in extracellular matrix degradation, MMP1 could be associated with fibrotic processes underlying RV remodeling, including dilation and hypertrophy. The additional biomarkers may not be specific towards cardiac remodeling. These findings merit further correlations with myocardial fibrosis measurements by CMR.
Sections du résumé
BACKGROUND
Serum biomarkers of myocardial fibrosis are considered markers of adverse outcome in adults with heart disease. Associations between biomarkers and clinical parameters in tetralogy of Fallot (TOF) has been understudied. We compared serum biomarker profiles with clinical and cardiac magnetic resonance (CMR) parameters of ventricular remodeling in patients with repaired TOF.
METHODS
Serum biomarkers [metalloproteinases MMP1 and MMP9, galectin-3, micro-RNA21 (miR21)), ST2, procollagen type I carboxy-terminal propeptide (PICP), and NTproBNP] were measured in TOF patients undergoing CMR. Associations between biomarkers and clinical and CMR variables were assessed using correlation coefficients, and linear and logistic regression.
RESULTS
Sixty patients were investigated, of which 47% were male. Age at CMR and TOF repair was 15 years [interquartile range (IQR) 9, 22] and 3.2 months (IQR 0.8, 6.2), respectively. Twelve (20%) had prior pulmonary valve replacement (PVR). MMP1 values were higher among those with prior PVR (16.7 (IQR 7.9, 25.5) vs 14.4 (IQR 9.9, 24.9), p = 0.02). When stratifying MMP1 into low and high groups, higher MMP1 was associated with higher indexed right (RV) and left ventricular (LV) mass and RV mass:volume ratios after adjusting for PVR. No other associations between biomarkers and CMR parameters were identified.
CONCLUSIONS
Only MMP1 was associated with markers of RV remodeling after TOF repair. As an enzyme involved in extracellular matrix degradation, MMP1 could be associated with fibrotic processes underlying RV remodeling, including dilation and hypertrophy. The additional biomarkers may not be specific towards cardiac remodeling. These findings merit further correlations with myocardial fibrosis measurements by CMR.
Identifiants
pubmed: 35487317
pii: S0167-5273(22)00582-4
doi: 10.1016/j.ijcard.2022.04.064
pmc: PMC10357342
mid: NIHMS1892961
pii:
doi:
Substances chimiques
Biomarkers
0
MIRN21 microRNA, human
0
MicroRNAs
0
Matrix Metalloproteinase 1
EC 3.4.24.7
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
27-33Subventions
Organisme : NHLBI NIH HHS
ID : K01 HL125521
Pays : United States
Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.
Références
Clin Chem. 1990 Jul;36(7):1328-32
pubmed: 2372946
Antioxid Redox Signal. 2019 Nov 10;31(14):1053-1069
pubmed: 30767565
Circulation. 2012 Sep 4;126(10):1206-16
pubmed: 22851543
J Pediatr. 2015 Aug;167(2):325-30.e1
pubmed: 26033368
Int J Cardiol. 2013 Sep 10;167(6):2963-8
pubmed: 22999338
Radiology. 1996 Oct;201(1):135-40
pubmed: 8816534
J Am Coll Cardiol. 2012 Oct 2;60(14):1249-56
pubmed: 22939561
Heart Lung Circ. 2017 Nov;26(11):1208-1215
pubmed: 28242288
Eur Heart J. 2010 Apr;31(7):794-805
pubmed: 20067914
Int J Cancer. 2016 Oct 15;139(8):1821-9
pubmed: 27281120
Radiology. 2011 May;259(2):375-83
pubmed: 21248236
J Cardiovasc Pharmacol. 2011 May;57(5):522-35
pubmed: 21423029
J Cardiovasc Magn Reson. 2017 Dec 11;19(1):100
pubmed: 29228952
Circulation. 2010 Apr 13;121(14):1645-54
pubmed: 20385961
Circulation. 1993 Nov;88(5 Pt 1):2257-66
pubmed: 8222120
Radiology. 2005 Dec;237(3):868-71
pubmed: 16304108
Diagnostics (Basel). 2021 Nov 13;11(11):
pubmed: 34829449
Am Heart J. 2011 Sep;162(3):467-73
pubmed: 21884862
Mol Med Rep. 2017 Jan;15(1):359-365
pubmed: 27922664
Eur J Heart Fail. 2012 Jan;14(1):74-81
pubmed: 22089058
J Am Coll Cardiol. 1997 Nov 1;30(5):1374-83
pubmed: 9350942
Circ Res. 2002 Dec 13;91(12):1082-4
pubmed: 12480806
J Am Soc Echocardiogr. 2010 Sep;23(9):912-8
pubmed: 20650609
J Thorac Cardiovasc Surg. 2006 Aug;132(2):270-7
pubmed: 16872949
Eur Heart J. 2005 Mar;26(5):433-9
pubmed: 15640261
Int J Clin Exp Pathol. 2014 Jan 15;7(2):565-74
pubmed: 24551276
J Am Coll Cardiol. 2006 Jul 4;48(1):89-96
pubmed: 16814653
J Am Coll Cardiol. 2004 Mar 17;43(6):1068-74
pubmed: 15028368
Heart. 2008 Feb;94(2):211-6
pubmed: 17135219
Circ J. 2014;78(3):693-700
pubmed: 24334564
Int J Biochem Cell Biol. 2019 Nov;116:105619
pubmed: 31561019
Eur Heart J Cardiovasc Imaging. 2013 Oct;14(10):978-85
pubmed: 23364871
Biomarkers. 2018 Nov;23(7):676-682
pubmed: 29737871
Lancet. 2000 Sep 16;356(9234):975-81
pubmed: 11041398
JACC Heart Fail. 2017 Apr;5(4):280-286
pubmed: 27816512
JACC Cardiovasc Imaging. 2016 Jan;9(1):67-81
pubmed: 26762877
Heart. 2016 Mar;102(5):390-6
pubmed: 26869635
N Engl J Med. 1993 Aug 26;329(9):593-9
pubmed: 7688102
Heart Vessels. 2016 Jun;31(6):939-46
pubmed: 25976729
Circulation. 2004 Sep 7;110(10):1263-8
pubmed: 15313958
Circ Cardiovasc Imaging. 2013 May 1;6(3):373-83
pubmed: 23553570
Circ Cardiovasc Imaging. 2012 Sep 1;5(5):637-43
pubmed: 22869820
Acta Cardiol Sin. 2018 Nov;34(6):511-517
pubmed: 30449992
J Cardiovasc Transl Res. 2010 Jun;3(3):251-5
pubmed: 20560046
J Am Coll Cardiol. 2013 Dec 10;62(23):2155-66
pubmed: 24076489